“The Power of Two: Effective Management of Severe Refractory Psoriasis Through Combined TYK2 and IL-23 Inhibition” (2025) SKIN The Journal of Cutaneous Medicine, 9(5), pp. 2669–2673. doi:10.25251/kj8rwg98.